ECOG randomized patients with advanced NSCLC to 1 of 4 new 3 of the 4 regimens used in ECOG docetaxel/cisplatin, paclitaxel/cisplatin. In the ECOG trial, the only direct comparison of similar regimens, response rates and survival times were similar between patients treated with cisplatin. ECOG was chosen as a plenary session presentation because it is an important trial that reflects the state of care in of metastatic NSCLC—the.
|Published (Last):||2 July 2012|
|PDF File Size:||10.86 Mb|
|ePub File Size:||16.29 Mb|
|Price:||Free* [*Free Regsitration Required]|
Close mobile search navigation Article navigation. A worse PS is characterised by lower response rates to chemotherapy, shorter time to treatment failure and shorter progression-free survival [ 27 eckg, 28 ].
Initially patients were eligible with performance status PS 0, 1, or 2. Prospective randomized trial of docetaxel 1549 best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. The docetaxel-platinum combination demonstrated broad QOL benefits for patients receiving this combination, and this benefit was not observed with the other platinum or taxane-platinum combinations. The study enrolled patients with a PS of between 0 and 2.
Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review
Patients who progressed were taken off the study. Despite the disappointing results of ECOGthere were notable trials describing new agents with novel mechanisms of action reported at this year’s ASCO meeting.
Clearly we have reached our limit in developing doublet platinum-based combinations for advanced NSCLC.
Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer. Ecot status as a prognostic factor. Results and conclusions of that meeting are presented in this paper.
Lung Cancer Highlights
Throughout the studies, lower ecov of grade 3 or 4 neutropenia were reported with the PCb combination, most notably demonstrated in the SWOG trial Fig. These data should of course be kept in mind when treating PS2 patients, who are at a higher risk of toxicity. Prognostic factors in advanced non-small-cell lung cancer: Calderoni A, Cerny T.
The VC regimen was associated with more serious toxicities and a lower dose intensity. Preliminary results in the supportive care setting. This rate of toxicity is similar to that seen in other trials in extensive SCLC.
There were three deaths on study on the irinotecan arm and one death on the etoposide arm. Antiemetic prophylaxis was administered to all patients, and patients receiving cisplatin received hydration.
At present, platinum-based combination chemotherapy is considered the standard treatment for advanced NSCLC, but it is still unclear if the benefit achieved with this treatment is restricted only to PS0 and PS1 patients, or also ecig to PS2 patients. N Engl J Med. Six patients treated with chemotherapy plus antibody had life-threatening hemoptysis and four died. PS2 patients reported the worst scores at baseline assessment.
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: In the ECOG trial, the only direct comparison of similar regimens, response rates and survival times were similar between patients treated with cisplatin plus either docetaxel or paclitaxel [ 15 ].
There were four key end points in these randomized trials for determining the relative merits of these regimens: The preclinical development of paclitaxel has been primarily performed in the U.
Google Scholar Articles by Rigas, J. Additional differences emerged when QOL data were evaluated. The study confirmed a substantial incidence of grade 3 and grade 4 toxicities in PS2 patients, although not significantly higher than in patients with better PS. New biological agents should be considered as excellent candidates for experimental treatments in clinical trials dedicated to PS2 patients, but as yet cannot be recommended in clinical practice.
For PS2 patients, grade 3—4 haematological toxicity occurred earlier and more frequently in the arm receiving vinorelbine—cisplatin than in the vinorelbine arm 7 1954 28 days after the start of treatment, respectively. Lung cancer in women: Survival determinants in extensive-stage non-small-cell lung cancer: However, the impressive response rate and the unusual eckg seen in these lesions is supportive of this drug having activity.
A consensus was reached that single-agent chemotherapy with one of the new agents e.